Targeting the unstable atherosclerotic plaque : diagnostic and therapeutic implications Segers, F.M.E.

Hele tekst

(1)Targeting the unstable atherosclerotic plaque : diagnostic and therapeutic implications Segers, F.M.E.. Citation Segers, F. M. E. (2010, May 6). Targeting the unstable atherosclerotic plaque : diagnostic and therapeutic implications. Retrieved from https://hdl.handle.net/1887/15348 Version:. Corrected Publisher’s Version. License:. Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden. Downloaded from:. https://hdl.handle.net/1887/15348. Note: To cite this publication please use the final published version (if applicable)..

(2) Chapter General Introduction. 1. Filip M.E. Segers 1. Cardiovascular Disease and Atherosclerosis

(3) 2.1 Plaque initiation 2.2 Plaque progression 2.3 Plaque stability and rupture.

(4)

(5)

(6)

(7) 3.1 Macrophages 3.2 T Lymphocytes.

(8)

(9) !

(10) 4.1 Scavenger Receptor Class A 4.2 CD40/CD40L Pathway 4.3 Chemokine and Chemokine Receptors. 5. Imaging in Atherosclerosis "# $ %

(11)

(12) %

(13) & '

(14) .

(15) 10.

(16) General Introduction. 1. Cardiovascular Disease and Atherosclerosis. 2. Pathogenesis of Atherosclerosis 2.1 PLAQUE INITIATION. 6 /

(17) % %0 ; %

(18) / + % %

(19)

(20)

(21) %%

(22) % +/

(23)

(24) %

(25) % %+/

(26) %

(27) /

(28)

(29) %+/ /

(30) % , 8 -

(31) / / - / :

(32) -

(33) + + %

(34) %

(35)

(36)

(37) %

(38)

(39) -+ % % +

(40)

(41) % +

(42)

(43)

(44) ; %+/ , / /

(45) %% /

(46) % % 7

(47)

(48) ! /

(49)

(50) %

(51)

(52) % : / %

(53) 8. %/

(54) =>&&-# 9, 10-

(55) % B

(56)

(57) H/J /

(58) ,

(59) %

(60) , %

(61)

(62)

(63) %

(64) H/ 6 /

(65) %

(66) %

(67)

(68) %

(69) /

(70)

(71)

(72)

(73) 11. Chapter 1. % % ()*

(74)

(75) +

(76) %

(77) ,

(78)

(79)

(80)

(81) )

(82) %

(83)

(84) -

(85) / - % / /

(86) %

(87) % 0/ % %

(88) 234

(89)

(90) 6 3 - 7

(91) /, % +/

(92) / - ),

(93) %1.

(94) % % +

(95)

(96) % /

(97) / / %

(98)

(99)

(100)

(101)

(102)

(103) % + 0 % -

(104) % /

(105) % % % -

(106) % in medium and large sized arteries at predisposed sites and characterized +/ %

(107) - 8+

(108)

(109)

(110) % % + 0". In the past decades, % % %

(111) : % ,

(112) + %

(113) ,

(114)

(115)

(116)

(117)

(118) ( /

(119)

(120) -/ % -

(121) %%+ *

(122) % /

(123)

(124)

(125) / % :

(126) - %

(127) / / -

(128) % % &. 4 ,%/ -

(129)

(130)

(131) %

(132) : ,

(133) %

(134) ,

(135) ; %

(136) %

(137) +

(138) 8 %%

(139) /- % , + %

(140)

(141) % % + %

(142) / %4 7 %

(143)

(144)

(145) -

(146)

(147)

(148)

(149) / % + %! ,-+ / % % %

(150) % :

(151) %

(152) / - ;+

(153)

(154) %

(155) 8

(156) /

(157)

(158) %

(159) ,

(160) 7

(161) % and diagnostic repertoire..

(162)

(163) %

(164) +

(165) -

(166) - %

(167)

(168) %

(169) !

(170) ,11. K

(171) % %/

(172)

(173) - , +

(174)

(175) % :

(176)

(177) % +/

(178) % 7

(179) %

(180) %

(181) 0= ()$0=*-

(182) %

(183) 0= ($0=*- K0

(184) %0

(185) L-=-=K7

(186) %

(187)

(188) % %

(189)

(190) %

(191) :

(192) (0*- ,

(193) % %

(194)

(195) %%

(196)

(197) : / -B

(198) J

(199)

(200) % /

(201) % +

(202)

(203)

(204)

(205) 0

(206) % H

(207)

(208)

(209) +0

(210) % -

(211) %%%

(212) %

(213) - N

(214) % %

(215) 0=(K$0=*

(216) %H

(217)

(218) %

(219) 0=(O$0=*=-=P

(220) %

(221)

(222) )$0=

(223) % $0=- , /

(224)

(225) 0 ()0*

(226) % / /

(227)

(228) %

(229)

(230) 0=(Q0=*- /-, 7 %

(231) : / ="0=L. '

(232)

(233)

(234)

(235) - : /

(236) %

(237) %

(238) !

(239) %

(240) / :

(241)

(242) 0R (4Q0 R*-

(243) /

(244) ($03Q*-

(245)

(246) 0T (Q40T*-

(247)

(248) , 0U(VQ0U*-

(249) :

(250) 0=U(0=U*

(251) %0$

(252) / ,%

(253)

(254) - ,

(255)

(256) %

(257)

(258) 0%

(259) %

(260)

(261) + / /

(262)

(263)

(264)

(265) %

(266) =>0.

(267)

(268)

(269) + %

(270) perturbed lipid homeostasis. Lipid transporting plasma proteins, the so called

(271)

(272) % / , %

(273) /

(274)

(275)

(276) / +

(277) % +

(278) % %/

(279)

(280)

(281) %

(282) , /

(283)

(284) % ,, /

(285)

(286) % 7%

(287) - /

(288) - .

(289)

(290) %

(291)

(292)

(293)

(294) 7 0P %8

(295) /

(296) %

(297) % + N

(298) % :

(299) %

(300)

(301) ;

(302)

(303) (3

(304) (3#*

(305) %X-

(306) 0 : 7%; % 0=( 70=*-"-"L* 7 %

(307) +

(308) % / accumulated macrophages- "- &

(309)

(310) %0 %

(311) $ %8 % ,0%

(312) /

(313) (*

(314) - : +/ -

(315) %

(316)

(317) +/

(318)

(319)

(320)

(321) !7 : /

(322) % 7

(323) %

(324)

(325) ! /

(326)

(327) ,

(328) %B/ : J

(329) %

(330) /

(331) % /

(332) + + (8 ==0X* 2.2 PLAQUE. PROGRESSION.

(333)

(334) %

(335) -

(336) ! /

(337)

(338) / %

(339) !

(340)

(341) %

(342) / / % % :

(343) Q - (3$J *

(344)

(345) % /

(346)

(347) / :

(348)

(349) % , - : 8+ + , (QVQ*

(350) % VQ0U- % % +/ %

(351) ! / '

(352) / : %

(353) ; - %0%

(354) ,

(355) % % 7

(356) % + - / 7

(357) % 0 12.

(358) General Introduction. B. A. Endothelial permeability. Leukocyte migration. Endothelial adhesion. Leukocyte adhesion. Smooth muscle migration. Foam cell formation. T-cell activation. Adherence and aggregation of platelets. Adherence and entry of leukocytes. D. C. Macrophage accumulation. Necrotic core formation. Fibrous cap formation. Plaque rupture. Thinning of fibrous cap. Hemorrhage from plaque microvessels. Figure 1.1.3 ,

(359) (*K

(360) % %/

(361)

(362) (X*Q/ :

(363) (*

(364)

(365)

(366)

(367) %

(368) %- % (* 2

(369) + - 0

(370) (% % # #4K

(371) O$ %=>>>*. 13. Chapter 1.

(372) ! /

(373) % 0 7%

(374)

(375) %

(376) % % % +

(377) % 7 % 6, & Q

(378)

(379)

(380) 0

(381) %

(382) 0

(383) ( % - 0

(384)

(385)

(386) %

(387) *'7%; % -

(388)

(389) 7%; %

(390) :

(391) +/ -

(392) %

(393) +/

(394) 7%; %

(395) %

(396) + %

(397) % lesions28

(398) 3$J

(399) ,%

(400) % , /,

(401) % % 7 7

(402)

(403) (

(404) *-

(405) 8+

(406) 7

(407) % :8+ 2

(408) %

(409)

(410) %

(411) - / %-

(412) :

(413) +

(414) +/ /

(415) 8+ cap. Moreover, due to a process called outward remodelling, the vessel is still +

(416)

(417)

(418)

(419) ; %

(420)

(421) ;

(422) ,

(423)

(424) % + %! ,29(8 ==*.

(425) 2.3 PLAQUE. STABILITY AND RUPTURE. [

(426) / ,% %

(427) %- %

(428) %

(429) %

(430)

(431) + % - %

(432) + %! ,

(433)

(434) %

(435) % 7

(436) 8+

(437) - %/

(438) Activated macrophages, T cells and other immune cells have been shown

(439) %

(440)

(441) %

(442) %

(443) atherosclerotic lesions&-]. Furthermore, activated macrophages, T cells, dendritic

(444) % +

(445) + % % - % - .

(446)

(447)

(448) +

(449) =0. % : / + % +/

(450) %

(451) 3$J , % % N

(452)

(453)

(454) %

(455) P- " . In addition these cells and in particular macrophages are also responsible %

(456)

(457) %

(458) 7% %

(459) 7

(460) ($$*&K /$$0=-$$0L-$$0>

(461) %$$0= +

(462) %,

(463) +/L0=. -

(464)

(465) / 7 % / :

(466)

(467) % 0 % % % +/

(468)

(469) ! / ,

(470) - ,

(471)

(472) /

(473) % - , % % +/

(474) ! / ,% %

(475) 7 ,, % % +

(476) + ,

(477) B8+ ^

(478) J-

(479) %

(480) / % % +/

(481) %

(482)

(483) % : 8+ '

(484) %/

(485) 7 % %/%

(486) % +/

(487) - 8+

(488) % +

(489)

(490)

(491) %

(492)

(493) %

(494) + %

(495) %

(496) , %

(497) %+ % + %-,/

(498) / - - % ,

(499) /

(500) -,, +

(501) % +/

(502) %

(503)

(504)

(505) / / %

(506)

(507)

(508) % : ](8 ==* As described above, immune responses during plaque initiation, progression

(509) %

(510)

(511) / %

(512) /

(513) % : / + ,

(514)

(515) -, 8/0 %%

(516) %

(517) %

(518)

(519) %

(520)

(521)

(522) + 7 % %

(523)

(524) %N %% % /

(525) %

(526)

(527) 0

(528)

(529) + : / +

(530) - ,

(531) 7 %+/ %

(532) -

(533)

(534) %,+ % %

(535) detail below.. 14.

(536) General Introduction. 3. Immune Cells in Atherosclerotic Lesion Development. 3.1 MONOCYTES/MACROPHAGES

(537)

(538) +

(539) % % +/ +:

(540) ,:

(541)

(542) ('N' *, K0N0 mice. Lesion prone ApoE0N0 ,

(543)

(544) %

(545) atherosclerosis&. 2

(546) %

(547)

(548) %

(549) -

(550)

(551)

(552)

(553)

(554) /

(555) % %

(556)

(557)

(558)

(559)

(560) -

(561)

(562) /

(563) % % + +

(564) %

(565) / ,

(566)

(567) - + / / H

(568)

(569)

(570)

(571) %

(572)

(573)

(574) ! /% 6

(575) / - + : 7%; %

(576)

(577) ( 3#0-3#0X-"*L0P=. 2: 7%; % ( 7*

(578)

(579) /

(580)

(581)

(582) % %

(583)

(584) - ,

(585)

(586) Q -

(587) % '7 % +/

(588) %

(589) %

(590) H +/ 7 ($6* :

(591) - % % / 7/

(592) - 0

(593) ! // :

(594)

(595) % , 0=U-4Q0R-Q40T

(596) %

(597) /

(598) ($*0=P0PP

(599) % 0

(600) ! /

(601) % %

(602) -

(603) %

(604) 8

(605)

(606) %

(607)

(608) ; 7 % %

(609) %

(610) $6 (#*, / %

(611)

(612)

(613) 8+ X :

(614)

(615) + %

(616) $6 %

(617)

(618)

(619) + % 7

(620) % %Q40T

(621)

(622) %

(623) 56'

(624) : 7% %%

(625) % 7 / :

(626) %+/ -

(627)

(628)

(629) % %

(630)

(631) , (Q*- / :

(632) -

(633) % 7

(634) ($$*

(635) %

(636)

(637)

(638) % destabilization.

(639) 8

(640)

(641) /

(642) +

(643) % - %

(644)

(645)

(646)

(647) %

(648)

(649)

(650)

(651) % %

(652)

(653) -

(654) %

(655) % % : 15. Chapter 1.

(656) % % - +

(657)

(658) /

(659) + 8 %

(660)

(661) ! /

(662) 0: % "- 0

(663) ! / /

(664)

(665)

(666)

(667)

(668) %

(669) =>L"-O

(670)

(671) P , 8 %

(672)

(673)

(674)

(675)

(676)

(677) % %

(678) /%

(679)

(680) % %/% %

(681) -

(682)

(683) % %

(684)

(685) ! /% Q -

(686) ,

(687) % + ,

(688)

(689)

(690) % : %

(691)

(692) %

(693) % - %

(694) % / / "..

(695)

(696) % %-

(697) % %/ ,

(698)

(699) : % /

(700) % +/P&. In this thesis

(701) %: / ,+

(702) % +

(703)

(704)

(705)

(706) %%

(707)

(708) . 3.2 T LYMPHOCYTES. 4 7 -

(709)

(710) +

(711)

(712)

(713) atherosclerotic lesions is the T cell. T cell presence in human atherosclerotic , %/ % + % , % % P. Antigen presenting cells

(714) / %

(715)

(716)

(717) 8

(718)

(719) % / %

(720)

(721) !

(722) (

(723) * :

(724)

(725)

(726) %

(727) % %

(728) % ,

(729)

(730) ,

(731) 8

(732)

(733) $6 - + X + helper and CD8+/ 7 %,

(734) %

(735)

(736) %

(737)

(738) + %

(739)

(740)

(741)

(742) % % %

(743)

(744)

(745) ! /% 58. H /

(746)

(747) - + +/ 59. A % 8

(748) /

(749) + T cells"]0" % % %

(750)

(751)

(752) 0

(753) '

(754)

(755) %-

(756)

(757) +

(758)

(759) % 8

(760) %N % ,

(761)

(762) %

(763) 60.

(764) +

(765)

(766) X %

(767) / :

(768) 8 - + helper T cells can be ; %

(769) , + ` = (=*

(770) % (* $ +

(771)

(772) = +/ = % 0

(773) ! /

(774) % 0

(775) / :

(776) (Q40T

(777) % 4Q0R*

(778) %

(779) +

(780)

(781) "-"Q40T

(782)

(783) %

(784) % ,

(785)

(786) % 7

(787) %

(788)

(789) % %

(790) 0

(791) ! // :

(792) and chemokines, and proteases. This process leads to renewed T cell recruitment ,

(793)

(794) , +/59, 65 6 ,

(795)

(796)

(797)

(798) 0=

(799) 0N0 %

(800) % %Q40T 7

(801)

(802) atherosclerotic lesions and in reduced lesion development66Th2 responses are %

(803) %

(804)

(805) 0

(806) %

(807)

(808)

(809) "-". In contrast with =-

(810) % % 0 % %

(811)

(812) 0

(813) / :

(814) 0-0P-0>-0=]-0=

(815) %0

(816) % ,

(817) VQ0U"& 0%

(818) %

(819)

(820) ; % % %

(821) 0P68-0=]">0&

(822) %VQ0U&0&" ,%

(823)

(824) / :

(825)

(826)

(827)

(828) 6 , -

(829) !

(830) % 7

(831) 0

(832) % + %

(833) %

(834)

(835)

(836) H

(837) 0

(838) % / ,

(839)

(840)

(841)

(842) &&, 0% 8

(843) /

(844) K0N0 mice resulted in reduced atherosclerotic lesion development as well&L

(845) /-0 %, 16.

(846) General Introduction. 4. Targeting the Unstable Atherosclerotic Plaque 4.1 SCAVENGER. RECEPTOR CLASS A (SR-A)

(847) =>&>-V %

(848)

(849) %X ,

(850) , 8 % +

(851) (3#J *

(852) % %

(853) /, + +

(854) %

(855) %

(856)

(857) ; %8 % , %

(858) /

(859) (*

(860)

(861)

(862) + %+/

(863)

(864) - %

(865) /

(866) : / culprits in macrophage cholesterol accumulationLP0L& 3#/

(867) L %

(868) + ( 0V*,

(869) +

(870) %

(871) %

(872) -

(873)

(874) - %8 %

(875) %+ %/ %8 %

(876) %

(877)

(878) 0

(879) % -

(880) %

(881) -

(882)

(883) %

(884) %/ % and pathogen components88. Macrophages in atherosclerotic lesions have +

(885) ,

(886) 7 7 / %

(887)

(888) . 17. Chapter 1.

(889) % $$ %

(890) - ,

(891) % +/&>.

(892) % +/ +

(893) -

(894) / ; % %+/ +

(895)

(896) =N

(897) ,% 0

(898) ! / =

(899) / 80. As mentioned earlier, CD8+ T cells are also present in atherosclerotic lesions, +%

(900)

(901) %-

(902)

(903) '

(904) %/,

(905) + +

(906) / L+ % 8

(907) /

(908)

(909) %

(910)

(911) K0N0 mice % 8

(912) 81- ,

(913) %/ , %

(914) L+ T cell activation82. V

(915)

(916)

(917)

(918) -

(919) % % /

(920) %

(921) % , 0

(922) %

(923) % % ,

(924) + % 8

(925) -

(926)

(927) % + -

(928)

(929)

(930) 0 8

(931) % % +/ (#*,

(932) , % 0$6 7

(933)

(934)

(935)

(936)

(937)

(938) %

(939)

(940) %+/ 0 / -, 7 % on the antigen presenting cell plasma membrane and bind to receptors on the -

(941) /,

(942)

(943)

(944)

(945) +/ #L. The best ; % 0 / L0X&

(946)

(947)

(948) % ]0 ]

(949)

(950) L

(951) =

(952) -

(953) +

(954) 0+

(955) % ]

(956) %

(957) % Q40T- / +

(958) %

(959) ]

(960) % Q40T

(961) 3/

(962)

(963) +

(964) % 7

(965) 0

(966) ! /

(967)

(968)

(969) %

(970) !

(971) 0

(972)

(973) / - %

(974)

(975)

(976) %

(977)

(978) 0

(979) + /

(980) , 0 / / %

(981)

(982)

(983) 0 / ,/

(984) / 7

(985)

(986)

(987)

(988)

(989) 0 % % %

(990) , ,

(991) ]0],/

(992) %

(993)

(994) %

(995)

(996)

(997) .

(998) : %8 % - ,

(999) 3#0 % %: %8 %

(1000) +

(1001)

(1002) - ,% /+ % /

(1003)

(1004)

(1005)

(1006) 0

(1007) ! /

(1008) / lesional macrophages89

(1009) , ,

(1010) /

(1011)

(1012) '

(1013) % X(3#0X=-"*- ( %3#0=*- ("L*- K( 70=*

(1014) % Q(

(1015) % 3#K*90(8 =*.. Figure 1.2. % ,

(1016) %

(1017) %

(1018)

(1019) /(% % $ fO - +) X - ]]"*. Structure, function and expression

(1020) (3#0*/

(1021)

(1022) % +/

(1023)

(1024)

(1025)

(1026) L91, 92 3#0 /

(1027) +

(1028) /

(1029)

(1030) /

(1031) - 3#0- 3#0

(1032) % 3#0 /- , %

(1033) /

(1034) 0%

(1035)

(1036) %N

(1037) : %

(1038)

(1039) +

(1040) %+

(1041) %

(1042) >. K

(1043)

(1044) " % % %

(1045) `

(1046) 40

(1047) / - transmembrane, spacer, R0 %0 -

(1048)

(1049) % / 0 8 + 7/

(1050) >0>"/ 3#0 /

(1051) %

(1052) ==]

(1053) % ,

(1054) %

(1055)